Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate. (1st July 2015)

• Record Type: Journal Article
• Authors: Gallant, Joel E.; Koenig, Ellen; Andrade-Villanueva, Jaime F.; Chetchotisakd, Ploenchan; DeJesus, Edwin; Antunes, Francisco; Arastéh, Keikawus; Rizzardini, Giuliano; Fehr, Jan; Liu, Hui C.; Abram, Michael E.; Cao, Huyen; Szwarcberg, Javier
• Is Part Of: Journal of acquired immune deficiency syndromes. Volume 69:Number 3(2015:Mar.)
• Publication Date: 2015-07-01
• Subjects: Cobicistat -- pharmacoenhancer -- HIV -- Antiretroviral -- clinical trial; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome -- Periodicals; AIDS (Disease); Periodicals; 616.9792005
• DOI: 10.1097/QAI.0000000000000598
• Languages: English
• ISSNs: 1525-4135

Abstract

Abstract : Background: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity. Methods: International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144. Results: At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48. Conclusions: Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.